Kyorin Pharmaceutical Co 4569.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4569.T. It has been listed since 10 March 2006. In the fiscal year to 31 March 2026, it reported revenue of ¥126.26bn and net income of ¥3.45bn. At that date it held total assets of ¥195.46bn and shareholders' equity of ¥142.43bn.

KYORIN Holdings, Inc. engages in the development, manufacture and sale of pharmaceutical products through its subsidiaries. The company is headquartered in Chiyoda-Ku, Tokyo-To. The company went IPO on 2006-03-10. The firm operates through two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sales of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, as well as the research of new drugs and candidate compounds. The company also engages in the purchase and sales of medical promotion tools and packaging materials. The Healthcare segment is engaged in the manufacturing, sales and purchase of environmental sanitation products, general purpose medicines and skin care products.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Yutaka OgiharaPresident, Chief Executive Officer, Representative Director, since 2011
• Mr. Yasuji KuroseChief Financial Officer, Chief Strategy Officer, Director of Business Planning, Director, since 2023
• Mr. Michiro OnotaChief Marketing Officer, President of Subsidiary, Director, since 2015
• Mr. Noriaki TamuraChief Compliance Officer, Executive Officer, Chief Director of Pharmaceutical Sales
• Mr. Kei TakahashiSenior Executive Officer, Chief Director of SCM
• Mr. Katsuhiro HamadaExecutive Officer, Chief Director of Quality Assurance & Reliability
• Mr. Hiroshi HashizumeExecutive Officer, President of Subsidiary
• Mr. Junichi IshiyamaExecutive Officer, Chief Scientific officer, Chief Director of Drug Discovery
• Mr. Takaaki KajiExecutive Officer, Chief Business Development Officer, Chief Director of Business Development
• Mr. Kimiya MasadaExecutive Officer, Director of Manufacturing Strategy
• Mr. Kenichi NakamuraExecutive Officer
• Mr. Kiyoo UeharaExecutive Officer, Director of General Affairs

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.